Alva’s Omega Diagnostics in Omicron test success

Alva-based Omega Diagnostics Group said on Tuesday that analysis from clinical samples shows that its Covid-19 antigen test performs with “the same high accuracy” on the Omicron variant.

“Omega … has been notified by its technology partner Mologic Ltd that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT COVID-19 antigen test.”

Omega Diagnostics CEO Colin King said: “We are very pleased be in a position to confirm that the VISITECT COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants.

“We remain encouraged by emerging commercial opportunities for our VISITECT COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use.”